These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 23945239)

  • 1. Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacy.
    Johnson L; Huseni M; Smyczek T; Lima A; Yeung S; Cheng JH; Molina R; Kan D; De Mazière A; Klumperman J; Kasman I; Zhang Y; Dennis MS; Eastham-Anderson J; Jubb AM; Hwang O; Desai R; Schmidt M; Nannini MA; Barck KH; Carano RA; Forrest WF; Song Q; Chen DS; Naumovski L; Singh M; Ye W; Hegde PS
    J Clin Invest; 2013 Sep; 123(9):3997-4009. PubMed ID: 23945239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab radiosensitizes non-small cell lung cancer xenografts by inhibiting DNA double-strand break repair in endothelial cells.
    Gao H; Xue J; Zhou L; Lan J; He J; Na F; Yang L; Deng L; Lu Y
    Cancer Lett; 2015 Aug; 365(1):79-88. PubMed ID: 25982206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with antiangiogenic agent.
    Shin SJ; Hwang JW; Ahn JB; Rha SY; Roh JK; Chung HC
    Invest New Drugs; 2013 Feb; 31(1):1-13. PubMed ID: 22539090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutrophil granulocyte derived MMP-9 is a VEGF independent functional component of the angiogenic switch in pancreatic ductal adenocarcinoma.
    Bausch D; Pausch T; Krauss T; Hopt UT; Fernandez-del-Castillo C; Warshaw AL; Thayer SP; Keck T
    Angiogenesis; 2011 Sep; 14(3):235-43. PubMed ID: 21442180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteasome inhibition with bortezomib induces cell death in GBM stem-like cells and temozolomide-resistant glioma cell lines, but stimulates GBM stem-like cells' VEGF production and angiogenesis.
    Bota DA; Alexandru D; Keir ST; Bigner D; Vredenburgh J; Friedman HS
    J Neurosurg; 2013 Dec; 119(6):1415-23. PubMed ID: 24093630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer.
    von Pawel J; Spigel DR; Ervin T; Losonczy G; Barlesi F; Juhász E; Anderson M; McCall B; Wakshull E; Hegde P; Ye W; Chen D; Chang I; Rhee I; Reck M
    Oncologist; 2018 Jun; 23(6):654-e58. PubMed ID: 29438092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts.
    Miyazaki S; Kikuchi H; Iino I; Uehara T; Setoguchi T; Fujita T; Hiramatsu Y; Ohta M; Kamiya K; Kitagawa K; Kitagawa M; Baba S; Konno H
    Int J Cancer; 2014 Jul; 135(2):295-307. PubMed ID: 24375080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms.
    Wagner J; Kline CL; Zhou L; Khazak V; El-Deiry WS
    J Exp Clin Cancer Res; 2018 Jan; 37(1):11. PubMed ID: 29357916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.
    Patterson DM; Gao D; Trahan DN; Johnson BA; Ludwig A; Barbieri E; Chen Z; Diaz-Miron J; Vassilev L; Shohet JM; Kim ES
    Angiogenesis; 2011 Sep; 14(3):255-66. PubMed ID: 21484514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sulfated fucoidan FP08S2 inhibits lung cancer cell growth in vivo by disrupting angiogenesis via targeting VEGFR2/VEGF and blocking VEGFR2/Erk/VEGF signaling.
    Chen H; Cong Q; Du Z; Liao W; Zhang L; Yao Y; Ding K
    Cancer Lett; 2016 Nov; 382(1):44-52. PubMed ID: 27569654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-126 and epidermal growth factor-like domain 7-an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial.
    Hansen TF; Christensen Rd; Andersen RF; Sørensen FB; Johnsson A; Jakobsen A
    Br J Cancer; 2013 Sep; 109(5):1243-51. PubMed ID: 23922111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual blockade of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2) exhibits potent anti-angiogenic effects.
    Li D; Xie K; Zhang L; Yao X; Li H; Xu Q; Wang X; Jiang J; Fang J
    Cancer Lett; 2016 Jul; 377(2):164-73. PubMed ID: 27130666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of bevacizumab on human malignant melanoma cells with functional VEGF/VEGFR2 autocrine and intracrine signaling loops.
    Adamcic U; Skowronski K; Peters C; Morrison J; Coomber BL
    Neoplasia; 2012 Jul; 14(7):612-23. PubMed ID: 22904678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting tumor-associated endothelial cells: anti-VEGFR2 immunoliposomes mediate tumor vessel disruption and inhibit tumor growth.
    Wicki A; Rochlitz C; Orleth A; Ritschard R; Albrecht I; Herrmann R; Christofori G; Mamot C
    Clin Cancer Res; 2012 Jan; 18(2):454-64. PubMed ID: 22065082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arsenic trioxide exerts anti-lung cancer activity by inhibiting angiogenesis.
    Yang MH; Zang YS; Huang H; Chen K; Li B; Sun GY; Zhao XW
    Curr Cancer Drug Targets; 2014; 14(6):557-66. PubMed ID: 25088040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VEGF-A/VEGFR-2 signaling plays an important role for the motility of pancreas cancer cells.
    Doi Y; Yashiro M; Yamada N; Amano R; Noda S; Hirakawa K
    Ann Surg Oncol; 2012 Aug; 19(8):2733-43. PubMed ID: 22207048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FP3: a novel VEGF blocker with anti-angiogenic and anti-tumor effects.
    Gao W; Jin K; Lan H; Han N; Cao F; Teng L
    Hepatogastroenterology; 2012; 59(120):2543-7. PubMed ID: 22534543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DSGOST inhibits tumor growth by blocking VEGF/VEGFR2-activated angiogenesis.
    Choi HS; Lee K; Kim MK; Lee KM; Shin YC; Cho SG; Ko SG
    Oncotarget; 2016 Apr; 7(16):21775-85. PubMed ID: 26967562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
    Hsu JY; Wakelee HA
    BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.